Atom Investors’s bluebird bio BLUE Stock Holding History

Atom Investors’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-698	Closed	-$13.7K	–	476
2024 Q2	$13.7K	Sell	698 -326	-32%	-$6.53K	﹤0.01%	457
2024 Q1	$26.2K	Buy	+1,024	New	+$26.2K	﹤0.01%	548

Other funds holding BLUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Atom Investors's BLUE Position: Q3 2024 in Review

Atom Investors sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 698 shares — an estimated $13.7K sold.

Atom Investors first reported a position in BLUE in Q1 2024 and held it in 2 quarters. The position peaked at $26.2K in Q1 2024. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

Atom Investors reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
Atom Investors sold 698 bluebird bio shares in Q3 2024, an estimated $13.7K.
Atom Investors first reported a position in bluebird bio in Q1 2024 and held it in 2 quarters.
Atom Investors's bluebird bio position peaked at $26.2K in Q1 2024.
140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Atom Investors's 13F filing for Q3 2024, filed 14 Nov 2024.